About the Company
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Pluri Inc.
Pluri Announces €1 Million Proof of Concept Agreement to ... - Nasdaq
With over 7.5 billion people currently, the global population is steadily rising and expected to reach 8.6 billion in 2030 and 11.2 billion by the turn of the century. About Pluri Inc.
Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak
Pluri Inc, formerly Pluristem Therapeutics, is a biotechnology research company developing medical, pharma, and food products from placenta-based stem cells R&D. Pluri's bitty revenue over decades ...
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a ...
--Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today unveiled a breakthrough in cell manufacturing that potentially solves ...
PLUR Stock Quote Price and Forecast | CNN
View Pluri Inc. PLUR stock quote prices, financial information, real-time forecasts, and company news from CNN.
Pluri Inc. Announces 1-for-8 Reverse Share Split - Nasdaq
--Pluri Inc., a leading biotechnology company that transforms cells into solutions, today announced that a reverse share split of the Company’ s issued and outstanding common shares, par value ...
Pluri Secures Additional $3.5 Million Investment from Major ... - Nasdaq
--Pluri Inc., a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the pricing of a private ...
Pluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology ...
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote ...
Pluri Inc. to enact 1-for-8 reverse stock split on April 1
Editor Emilio Ghigini Company News Editor Emilio Ghigini Published03/27/2024, 07:08 AM Pluri Inc. to enact 1-for-8 reverse stock split on April 1 View all comments (0)0 PLUR 0.00% ...
Pluri Announces €1 Million Proof of Concept Agreement to Enhance ...
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and ...
Pluri Inc. Announces 1-for-8 Reverse Share Split - Seeking Alpha
Pluri Inc. Announces 1-for-8 Reverse Share Split Mar. 27, 2024 7:00 AM ET Pluri Inc. (PLUR) ...
Pluri Inc. to enact 1-for-8 reverse stock split on April 1
Despite not being profitable over the last twelve months, Pluri Inc. has shown impressive revenue growth, with a quarterly increase of 5150.0% in Q2 2024.
Similar Companies
Loading the latest forecasts...